Novo Nordisk
Novo Nordisk’s Wegovy reduces risk of cardiovascular events
August 9, 2023Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide
Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …
Novo Nordisk invests DKK 15.9bn to expand API production in Denmark
June 13, 2023Manufacturing and Production APIs, Chronic Diseases, Novo Nordisk, chronic diseases
Danish healthcare company Novo Nordisk has announced that it will invest another DKK 15.9bn into expanding an existing Active Pharmaceutical …
UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity
June 7, 2023Research and Development NHS, Novo Nordisk, Obesity, Wegovy, clinical trial, obesity
The UK Government has announced plans to launch a pilot programme which will provide GPs with Novo Nordisk’s Wegovy (semaglutide), …
Novo Nordisk to expand obesity study into oral treatment
April 22, 2021Novo Nordisk, obesity
Novo Nordisk is planning to initiate a Phase IIIa study of oral semaglutide in obesity, expanding on its Phase IIIa …
Novo Nordisk obesity treatment successful in clinical trials
March 24, 2021Research and Development Novo Nordisk, obesity
New results from Novo Nordisk’s Phase III study on obesity saw clinically relevant weight loss, without weight regain, in people …
FDA approves Novo Nordisk’s Saxenda for adolescent obesity
December 7, 2020Sales and Marketing FDA, Novo Nordisk, saxenda
The FDA has awarded US approval to Novo Nordisk’s Saxenda (liraglutide) 3mg injection to treat obesity in patients between the …
NICE recommends Novo’s liraglutide for management of obesity and non-diabetic hyperglycaemia
October 30, 2020Medical Communications, Sales and Marketing NICE, Novo Nordisk, liraglutide
Novo Nordisk’s pre-filled injection Saxenda (liraglutide) has received the backing of drug watchdog NICE, meaning it will now be made …
Novo Nordisk launches new Rybelsus pill for type 2 diabetes in the UK
September 2, 2020Research and Development Novo Nordisk, diabetes, type 2, type 2 diabetes
Novo Nordisk’s new type 2 diabetes treatment Rybelsus is now available for doctors and physicians in the UK to prescribe …
European approval for Novo’s Rybelsus to control blood sugar in type 2 diabetes
April 6, 2020Sales and Marketing Novo Nordisk, Rybelsus, diabetes, pharma
The European Commission has greenlighted Novo Nordisk’s Rybelsus (oral semaglutide) as an adjunct to diet and exercise to improve glycaemic …
Novo Nordisk halts three haemophilia studies after participants suffer thrombotic events
March 17, 2020Manufacturing and Production, Research and Development Novo Nordisk, haemophilia, pharma
Novo Nordisk has moved to temporarily shut down two of its Phase 3 and one of its Phase 2 clinical …
NICE refuses Novo Nordisk’s obesity therapy Saxenda for NHS use
January 27, 2020Sales and Marketing NHS, NICE, Novo Nordisk, UK, obesity, saxenda
NICE, the drug watchdog for England and Wales, has revealed that it has chosen not to recommend Novo Nordisk’s Saxenda …
Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD
January 17, 2020Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma
Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …
Novo Nordisk to offer US patient’s in immediate need free insulin
January 3, 2020Medical Communications Novo, Novo Nordisk, Type 1 diabetes, diabetes, insulin, type 2 diabetes
Novo Nordisk said it would offer free, one-time supply of insulin to those in need, amidst rising insulin prices. Novo …
Novo Nordisk opens first Pharmatech branch office in Singapore
October 22, 2019Manufacturing and Production Novo Nordisk, Singapore, pharma
Novo Nordisk has celebrated the launch of a new Pharmatech A/S branch office based in Singapore at a grand opening …
Novo’s Tresiba lowers hypoglycaemia risk compared to insulin glargine in type 2 diabetes
September 20, 2019Medical Communications, Research and Development Novo Nordisk, Tresiba, diabetes, pharma
Novo Nordisk has unveiled new data for Tresiba (insulin degludec) at the 55th Annual Meeting of the European Association for …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
